WASHINGTON - As the health reform legislation faces the difficult compromise road ahead during the upcoming conference process in January, little is expected to change with the measures affecting biotech, including the provisions to create a pathway for approval of follow-on biologics (FOBs). (BioWorld Today) Read More
